Onconetix (ONCO) investor relations material

Company overview and business model

• Commercial-stage biotechnology firm focused on oncology diagnostics, primarily through Proclarix, a protein-based blood test for prostate cancer, with commercialization efforts in the EU and planned US launch via LabCorp partnership.

• Acquired Proteomedix in December 2023, gaining Proclarix, and abandoned commercialization of ENTADFI due to resource constraints and impaired assets.

• Relies on third-party manufacturing and distribution, with LabCorp holding exclusive US commercialization rights for Proclarix.

• Ongoing clinical validation studies for Proclarix in the US, targeting expanded market adoption.

Financial performance and metrics

• As of June 30, 2026: cash of $5.9M, working capital of $3.6M, and accumulated deficit of $138.3M.

• Net losses since inception; $14.0M loss in 2025 and $58.7M in 2024; negative operating cash flows persist.

• Current cash balance insufficient to fund operations for one year; substantial doubt exists about ability to continue as a going concern.

Use of proceeds and capital allocation

• No proceeds will be received from the resale of shares by the selling stockholder; proceeds from prior PIPE financings used for operations and debt repayment.

• Future capital needs expected to be met through additional equity or debt financings, strategic partnerships, and product revenue from Proclarix.